Company intelligence / Profile preview
Tenex Therapeutics
Chapel Hill, North Carolina, United Statestenaxthera.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Phase 3
01
Overview
Tenax Therapeutics is a late-stage clinical pharmaceutical company focused on novel cardiopulmonary therapies. Its lead programs are in Phase 3 development for pulmonary arterial hypertension and pulmonary hypertension associated with heart failure with preserved ejection fraction. TNX‑201 (oral imatinib) has shown strong efficacy signals in prior studies for PAH, while TNX‑103 (oral levosimendan) is the first therapy to show efficacy in PH-HFpEF patients.
- Therapeutic areas
- Cardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Orion Corporation
Beyond the preview
Go deeper on Tenex Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tenex Therapeutics.